What Are the Challenges to Bring mRNA Therapies/mRNA-based Drugs to Market?

Discover how lipid nanoparticles (LNPs) can offer a safe and efficient delivery method for delicate mRNA molecules. In this video, Eleni Samaridou, Principal Scientist at Merck, discusses why overcoming the challenges in mRNA delivery is key to bring mRNA therapies to patients. Giving an overview on lipid nanoparticles (LNPs), she explains how LNPs provide a protective bubble for the delicate mRNA molecules enabling safe and efficient delivery to the cells. Eleni and her teammates are specialized in in developing custom LNP formulations for the preclinical phase. Discover how our Early Formulation Screening Service can support in screening and optimizing LNP formulations for your nucleic acid payloads. If you're interested in learning more about how to bring mRNA therapies to patients safely, this video is for you!
For additional information about our LNP CDTMO Services, visit our website: www.sigmaaldrich.com/services/contract-manufacturing/mrna-and-lnp-formulation-ctdmo-services/lipid-nanoparticle-cdmo-services